US EditionBioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
- BioVaxys and Horizon Technology Finance Corporation executed an amendment on May 29, 2025, to their Asset Purchase Agreement dated February 11, 2024, in Vancouver, BC.
- The amendment follows earlier revisions, reducing a required capital raise milestone from USD 10 million by December 31, 2024, to USD 2,028,636 by September 30, 2025, with the original deadline extended previously to June 30, 2025.
- The amended agreement replaces Section 12 terms, allows the milestone to include equity, grants, licensing fees, or loans, and provides for BioVaxys to issue share purchase warrants to Horizon and Powerscourt expiring May 31, 2028.
- BioVaxys is a clinical-stage biopharmaceutical company using DPX immune-educating and HapTenix 'neoantigen' platforms to develop treatments for cancers and other diseases, with its lead candidate, MVP-S, in Phase IIB trials for lymphoma and ovarian cancer.
- This amendment reflects BioVaxys' need to adjust financing conditions amid uncertainties in vaccine development, clinical approval, and commercial acceptance, while maintaining ongoing obligations and licensing terms through 2033.
Insights by Ground AI
Does this summary seem wrong?
55 Articles
55 Articles
All
Left
9
Center
13
Right
2
BioVaxys And Horizon Technology Finance Corp. Execute Amendment To Asset Purchase Agreement - Canadian Manufacturing
VANCOUVER — BioVaxys Technology Corp. announces that the Company and Horizon Technology Finance Corporation have executed a follow-on Amendment to the Asset Purchase Agreement dated February 11th, 2024 for acquiring the entire portfolio of assets and intellectual property based on the DPX immune educating platform technology developed by Canadian biotechnology company, IMV Inc. Section 12 of the February 11th, 2024 APA is a performance milestone…
Coverage Details
Total News Sources55
Leaning Left9Leaning Right2Center13Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 38%
C 54%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
